Investigation of HIFU-induced anti-tumor immunity in a murine tumor model-3

<p><b>Copyright information:</b></p><p>Taken from "Investigation of HIFU-induced anti-tumor immunity in a murine tumor model"</p><p>http://www.translational-medicine.com/content/5/1/34</p><p>Journal of Translational Medicine 2007;5():34-34.</p><p>Published online 11 Jul 2007</p><p>PMCID:PMC1939831.</p><p></p>FSE-labeled immature bone marrow-derived DCs were injected into tumor 1 day after HIFU treatment. The (A) total cell number, (B) total number of DC(CD11ccells), and (C) migrating DC (CFSECD11ccells) recovered in DLN on day 2 were determined by flow cytometry. Data points represent the mean ± SD for each group (n = 8). *P < 0.05 versus DC injection only control group. (D) Representative histogram illustrating the population of CFSECD11ccells within the DLN of mice subjected to different treatments

Investigation of HIFU-induced anti-tumor immunity in a murine tumor model-4

<p><b>Copyright information:</b></p><p>Taken from "Investigation of HIFU-induced anti-tumor immunity in a murine tumor model"</p><p>http://www.translational-medicine.com/content/5/1/34</p><p>Journal of Translational Medicine 2007;5():34-34.</p><p>Published online 11 Jul 2007</p><p>PMCID:PMC1939831.</p><p></p>ors, and induced tumor-specific CTL response (C), and IFN-γ-secreting cells (D) in the spleens of treated mice. C57BL/6 mice were inoculated s.c. on right hind leg with 5 × 10MC38 tumor cells and treated with different HIFU on day 9 of tumor inoculation. Mice were challenged with 1 × 10MC38 tumor cells by s.c. inoculation on the left hind leg one day after HIFU treatment. Both primary and challenged tumor growth were monitored daily. Splenocytes obtained from control and treated mice 10 days after HIFU treatment were re-stimulated with mytomicin-pretreated MC-38 or EL4 tumor cells and CTL and ELISPOTS assays were performed. Results were expressed as mean value ± SD for each group (n = 8). *P < 0.05; **P < 0.001 versus non-treatment control. This experiment is representative of three experiments with consistent results

Investigation of HIFU-induced anti-tumor immunity in a murine tumor model-6

<p><b>Copyright information:</b></p><p>Taken from "Investigation of HIFU-induced anti-tumor immunity in a murine tumor model"</p><p>http://www.translational-medicine.com/content/5/1/34</p><p>Journal of Translational Medicine 2007;5():34-34.</p><p>Published online 11 Jul 2007</p><p>PMCID:PMC1939831.</p><p></p>ing. Bright hyperechoic spots generated by HIFU indicate regions of cavitation

Investigation of HIFU-induced anti-tumor immunity in a murine tumor model-1

<p><b>Copyright information:</b></p><p>Taken from "Investigation of HIFU-induced anti-tumor immunity in a murine tumor model"</p><p>http://www.translational-medicine.com/content/5/1/34</p><p>Journal of Translational Medicine 2007;5():34-34.</p><p>Published online 11 Jul 2007</p><p>PMCID:PMC1939831.</p><p></p>ing. Bright hyperechoic spots generated by HIFU indicate regions of cavitation

Investigation of HIFU-induced anti-tumor immunity in a murine tumor model-2

<p><b>Copyright information:</b></p><p>Taken from "Investigation of HIFU-induced anti-tumor immunity in a murine tumor model"</p><p>http://www.translational-medicine.com/content/5/1/34</p><p>Journal of Translational Medicine 2007;5():34-34.</p><p>Published online 11 Jul 2007</p><p>PMCID:PMC1939831.</p><p></p>llected 1–2 days after HIFU treatment. 6-μm cryostat sections were cut and stained with anti-CD11c Abs. Then the antibody was visualized using the Anti-Hamster Ig HRP detection kit. The sections were counterstained with hematoxylin

Investigation of HIFU-induced anti-tumor immunity in a murine tumor model-0

<p><b>Copyright information:</b></p><p>Taken from "Investigation of HIFU-induced anti-tumor immunity in a murine tumor model"</p><p>http://www.translational-medicine.com/content/5/1/34</p><p>Journal of Translational Medicine 2007;5():34-34.</p><p>Published online 11 Jul 2007</p><p>PMCID:PMC1939831.</p><p></p>cavitation detection (PCD) signals, and (C) images of tumor tissue injury produced by different HIFU treatment

Investigation of HIFU-induced anti-tumor immunity in a murine tumor model-5

<p><b>Copyright information:</b></p><p>Taken from "Investigation of HIFU-induced anti-tumor immunity in a murine tumor model"</p><p>http://www.translational-medicine.com/content/5/1/34</p><p>Journal of Translational Medicine 2007;5():34-34.</p><p>Published online 11 Jul 2007</p><p>PMCID:PMC1939831.</p><p></p>cavitation detection (PCD) signals, and (C) images of tumor tissue injury produced by different HIFU treatment

Long term disease-free survival and T cell and antibody responses in women with high-risk Her2+ breast cancer following vaccination against Her2-0

<p><b>Copyright information:</b></p><p>Taken from "Long term disease-free survival and T cell and antibody responses in women with high-risk Her2+ breast cancer following vaccination against Her2"</p><p>http://www.translational-medicine.com/content/5/1/42</p><p>Journal of Translational Medicine 2007;5():42-42.</p><p>Published online 6 Sep 2007</p><p>PMCID:PMC2042490.</p><p></p>intracellular IFNγ at weeks 0, 1, 3, 6, and 10. Stimulated cells were fixed, permeabilized and stained with αIFNγ-FITC, αCD69-PE, αCD8-PerCP and αCD4-APC. The percent of CD4+ and CD8+ T cells that are IFNγ and CD69 double positive are represented for each antigen. Cells were gated by forward and side scatter for lymphocytes and positively for CD8 or CD4. Arrows represent when the patient was given each vaccination: week 0, 3, 6 and 9. The x-axis represents week of analysis and y-axis represents percent CD4+ or CD8+ cells that are CD69+IFNγ+ in response to each antigen

Long term disease-free survival and T cell and antibody responses in women with high-risk Her2+ breast cancer following vaccination against Her2-1

<p><b>Copyright information:</b></p><p>Taken from "Long term disease-free survival and T cell and antibody responses in women with high-risk Her2+ breast cancer following vaccination against Her2"</p><p>http://www.translational-medicine.com/content/5/1/42</p><p>Journal of Translational Medicine 2007;5():42-42.</p><p>Published online 6 Sep 2007</p><p>PMCID:PMC2042490.</p><p></p>king with 1% BSA in PBS for 2 hours, serially diluted patients' sera (200 μl/well) were added to the wells in triplicate and incubated overnight at 4°C. Control serum from a normal donor was used as a negative control. Alkaline phosphatase conjugated anti-human IgG was added to the plate after washing, and color was developed using p-nitrophenyl phosphate. Absorbance at 405 nm was measured and the differences from the control serum at each dilution was plotted. The data represents the mean absorbance for each serum dilution ± standard deviation for each patient depicted

Precision and linearity targets for validation of an IFNγ ELISPOT, cytokine flow cytometry, and tetramer assay using CMV peptides-0

Nd ELISPOT assays. Circles represent donor 41; triangles, donor 68; and squares, donor 43. Open symbols represent CMV pp65responses; closed symbols represent CMV pp65 peptide mix responses (CFC and ELISPOT assays only). Note that certain responses were very similar, so some symbols overlap. Error bars represent the SD of 10 times that the six replicates were repeated. The gray zones indicate the area within which a laboratory doing validation could expect their data to lie.<p><b>Copyright information:</b></p><p>Taken from "Precision and linearity targets for validation of an IFNγ ELISPOT, cytokine flow cytometry, and tetramer assay using CMV peptides"</p><p>http://www.biomedcentral.com/1471-2172/9/9</p><p>BMC Immunology 2008;9():9-9.</p><p>Published online 17 Mar 2008</p><p>PMCID:PMC2275721.</p><p></p